Author | Masatoshi Kudo, MD, PhD | OncLive

Author | Masatoshi Kudo, MD, PhD

Articles

Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

September 16, 2018

Video

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

Dr. Kudo Discusses TACE Plus Sorafenib in HCC

February 15, 2018

Video

Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).

x